-
Tanshinol Inhibits the Growth, Migration and Invasion of Hepatocellular Carcinoma Cells via Regulating the PI3K-AKT Signaling Pathway [Retraction]
-
Dual PI3K/AKT and CDK4/6 inhibition reveals selective sensitivity in an SHH medulloblastoma stem cell model
-
The Interaction of PI3K/AKT/mTOR Pathway with the Tumor Microenvironment: A Dual Engine Driving Breast Cancer Progression and Reshaping Treatment Strategies
-
miR-218 Overexpression Suppresses Tumorigenesis of Papillary Thyroid Cancer via Inactivation of PTEN /PI3K/AKT Pathway by Targeting Runx2 [Retraction]
-
Correction to “Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma”
-
Synergistic Antitumor Activity of HAT Inhibitor A485 and XPO1 Inhibitor KPT8602 in Multiple Myeloma
-
The Luo-Dingyuan Thyroid Vascular-Lymphatic Segmentation Classification: A Functional Anatomy-Based Framework to Facilitate Precision Management and Thyroid Function Preservation
-
RETRACTION: Delanzomib, a Novel Proteasome Inhibitor, Sensitizes Breast Cancer Cells to Doxorubicin‐Induced Apoptosis
-
EXPRESSION OF CONCERN: A Newly Identified 45‐kDa JAK2 Variant with an Altered Kinase Domain Structure Represents a Novel Mode of JAK2 Kinase Inhibitor Resistance
-
Correction to “Effects of Autophagy Inhibition by SAR405, a Selective VPS34 Inhibitor, on Pleural Mesothelioma Cells”
-
MFAP2 Promotes Epithelial–Mesenchymal Transition in Gastric Cancer Cells by Activating TGF-β/SMAD2/3 Signaling Pathway [Retraction]
-
Notch3/4 Knockdown Inhibits Colon Adenocarcinoma Progression by Suppressing Tumor Cell Activity and Orchestrating VEGFA‐Dependent Tumor Immune Microenvironment
-
Real‐World Survival Over 25 Years in Extensive‐Stage Small‐Cell Lung Cancer: The Impact of Immune Checkpoint Inhibitors
-
Innovative fertility preservation strategies and programs for young adults with cancer
-
In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses
-
Health Disparities in Acute Myeloid Leukemia Patients Undergoing Treatment with Tyrosine Kinase Inhibitor (TKI) Therapy Targeting FLT3, IDH1, or IDH2
-
MiR-153-3p Suppresses Cell Proliferation, Invasion and Glycolysis of Thyroid Cancer Through Inhibiting E3F3 Expression [Retraction]
-
Impact of Targeted Immune Checkpoint Inhibitor Adjuvant Therapy on Recurrence-Free Survival and Functional Recovery in Stage III Tongue Cancer Patients: A Retrospective Cohort Study
-
Bladder-Preserving Platforms for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer
-
RETRACTION: Novel C‐Terminal Heat Shock Protein 90 Inhibitors Target Breast Cancer Stem Cells and Block Migration, Self‐Renewal, and Epithelial–Mesenchymal Transition
-
Prognostic and Predict Value of Peripheral Blood Circulating Tumor Cells Programmed Death‐Ligand 1 Expression and F‐18‐Fluorodeoxyglucose Metabolic Parameters in Patients With Advanced Non‐Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors
-
TNFAIP3 Reprograms T Cell Exhaustion and Restores Anti-Leukemia Immunity in Acute Myeloid Leukemia
-
Correction to “Mifepristone increases mRNA translation rate, triggers the unfolded protein response, increases autophagic flux, and kills ovarian cancer cells in combination with proteasome or lysosome inhibitors”
-
lncRNA CASC9 Regulates Cell Migration and Invasion in Hemangioma Endothelial Cells by Targeting miR-125a-3p/Nrg1 [Retraction]
